MARKET OVERVIEW
The India Pharmaceutical Market was valued at USD 61.36 Billion in 2024 and is forecasted to reach USD 174.31 Billion by 2033, growing at a CAGR of 11.32% during 2025-2033. The market is propelled by strong generic drug production, cost-efficient manufacturing, a skilled workforce, increasing domestic healthcare demand, and government support for local API production alongside advancements in biotechnology.The report presents a thorough review featuring the India Pharmaceutical Market growth, share, trends, and research of the industry.
STUDY ASSUMPTION YEARS
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
INDIA PHARMACEUTICAL MARKET KEY TAKEAWAYS
- Current Market Size: USD 61.36 Billion in 2024
- CAGR: 11.32% (2025-2033)
- Forecast Period: 2025-2033
- The market is a leading global supplier of affordable medicines driven by generics and skilled workforce.
- Chronic therapeutic drugs accounted for 38.1% of the market in the 12 months leading up to January 2024.
- Government initiatives like the Production-Linked Incentive (PLI) scheme support local API manufacturing.
- India’s biotechnology sector received ₹1,000 crore investment in 2024 to advance healthcare solutions.
- Expanding healthcare infrastructure and regulatory reforms continue to sharpen India’s global pharmaceutical leadership.
Sample Request Link: https://www.imarcgroup.com/india-pharmaceutical-market/requestsample
MARKET TRENDS
India is focusing on self-reliance in Active Pharmaceutical Ingredients (API) production. With government initiatives such as the Production Linked Incentive (PLI) scheme, domestic API manufacturing is being strengthened to reduce import dependence. Notably, in the first half of FY25 (April-September 2024), Rs. 604 crore (USD 69.76 million) was allocated under the PLI scheme for the pharmaceutical sector. This bolsters supply chain resilience and capacity to meet both domestic and international demand.
Biologics and biosimilars represent significant growth drivers in India’s pharmaceutical market. The biosimilars market is expected to expand at a CAGR of 22%, reaching USD 12 billion by 2025 and constituting approximately 20% of the pharmaceutical market. These developments cater to unmet medical needs in oncology, autoimmune diseases, and diabetes and are increasingly targeting export markets given India’s cost-effective production expertise.
Digitization is transforming pharmaceutical operations with automation, AI, and data analytics enhancing manufacturing, supply chain efficiencies, and patient care. About 79% of pharma leaders emphasize AI/ML adoption for drug discovery and clinical development, while 50% regard regulatory simplification as essential for growth. Telemedicine and e-pharmacies also improve medication accessibility, positioning India as a technologically advanced pharmaceutical hub.
MARKET GROWTH FACTORS
The growing prevalence of chronic diseases such as diabetes and cardiovascular conditions is driving demand for cost-effective medications. Chronic therapeutic drugs accounted for 38.1% of the market in the 12 months before January 2024. Heightened healthcare awareness and improved rural medical access further stimulate domestic market growth. India’s competitive advantage in quality, affordable medicines supports both local and international market strength.
Government support via schemes like the Production-Linked Incentive (PLI) encourages local API manufacturing, reducing imports and fostering self-reliance. In 2024, the Government of India allocated ₹1,000 crore to accelerate biotechnology innovations, boosting research in biosimilars and specialized therapies. Private and foreign investments are also enhancing the pharmaceutical ecosystem, expanding healthcare infrastructure and reforming regulations to propel growth.
India’s powerful generics production, economical manufacturing systems, and capable workforce underpin market expansion. Initiatives to expand healthcare infrastructure combined with increased R&D funding—like the Rs 5,000 crore government scheme launched in September 2023—have improved drug availability and pricing. This supports treatment accessibility for chronic and acute disorders, reinforcing India’s pharmaceutical growth trajectory.
MARKET SEGMENTATION
Analysis by Type:
- Pharmaceutical Drugs
- Cardiovascular Drugs
- Dermatology Drugs
- Gastrointestinal Drugs
- Genito-Urinary Drugs
- Hematology Drugs
- Anti-Infective Drugs
- Metabolic Disorder Drugs
- Musculoskeletal Disorder Drugs
- Central Nervous System Drugs
- Oncology Drugs
- Ophthalmology Drugs
- Respiratory Diseases Drugs
- Biologics
- Monoclonal Antibodies (MAbS)
- Therapeutic Proteins
- Vaccines
Pharmaceutical drugs dominate the market due to widespread healthcare solution provision, supported by growing health awareness and chronic disease cases. Government initiatives bolster healthcare infrastructure and promote innovation, enhancing availability and affordability.
Analysis by Nature:
- Organic
- Conventional
Conventional drugs lead due to broad use in acute and chronic disease treatment with established efficacy and affordability. The segment benefits from India’s strength in generics manufacturing, ensuring cost-efficiency and availability.
REGIONAL INSIGHTS
North India is the largest regional segment, supported by dense population, advanced healthcare infrastructure, and rising healthcare awareness. In 2024, Delhi’s Mohalla clinics recorded 1.39 crore appointments, enhancing local pharmaceutical infrastructure. The region’s strategic location and logistics strengthen supply chains to serve both domestic and international markets.
RECENT DEVELOPMENTS & NEWS
In January 2024, Glenmark Pharmaceuticals and Pfizer launched Abrocitinib for atopic dermatitis in India, marketed as JABRYUS and CIBINQO. June 2024 saw Orchid Pharma launch Cefepime-Enmetazobactam, an antibiotic, collaborating with Cipla for distribution. In December 2024, Mankind Pharma acquired Bharat Serums and Vaccines for INR 13,630 crores to boost women’s health and critical care. Mankind Pharma also licensed sintilimab from Innovent Biologics to enhance cancer treatment. Lupin Limited acquired Huminsulin from Eli Lilly in December 2024 to strengthen its diabetes portfolio.
KEY PLAYERS
- Abbott India Limited
- Aurobindo Pharma Limited
- Biocon Limited
- Cadila Pharmaceuticals
- Cipla Limited
- Divi’s Laboratories Limited
- Dr. Reddy’s Laboratories Ltd
- GSK plc
- Lupin Limited
- Mankind Pharma Limited
- Novartis India (Novartis AG)
- Pfizer Inc
- Procter & Gamble Health Limited
- Sun Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
ABOUT US
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
CONTACT US
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
Experienced Content Writer with a demonstrated history of working in the Health, Education, Technology, and Travel industry.